Skip to main content
Fig. 8 | Inflammation and Regeneration

Fig. 8

From: Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis

Fig. 8

Forest plot: a meta-analysis of the duration of SARS-CoV-2 RNA positivity in the upper respiratory tract samples based on the usage of glucocorticoid. The duration of SARS-CoV-2 RNA positivity from the onset of COVID-19 in the patients treated with glucocorticoid (a) and the patients treated without glucocorticoid (b) was calculated using the random effects model. The duration of SARS-CoV-2 RNA positivity from the onset of COVID-19 in the patients treated with glucocorticoid (c) and the patients treated without glucocorticoid (d) from the studies with the mean age of 30–60 years and the proportion of patients with any comorbidities of 50% or less was calculated using the random effects model. MRAW, the raw data of mean; 95%-CI, 95% confidence interval

Back to article page